Evidence map›Paper›PMID 29263442›Full record

Trial reportLeukemia2018

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

A Pardanani, J Gotlib, A W Roberts, M Wadleigh, S Sirhan, J Kawashima, J A Maltzman, L Shao, V Gupta, A Tefferi

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.Therapeutics and clinical risk management · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

A PardananiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
J GotlibStanford Cancer Institute, Stanford, CA, USA.
A W RobertsClinical Hematology & BMT, Royal Melbourne Hospital, and University of Melbourne, Parkville, Australia.
M WadleighDeparment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
S SirhanDivision of Hematology, Jewish General Hospital, Montreal, QC, Canada.
J KawashimaGilead Sciences, Inc, Foster City, CA, USA.
J A MaltzmanGilead Sciences, Inc, Foster City, CA, USA.
L ShaoGilead Sciences, Inc, Foster City, CA, USA.
V GuptaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
A TefferiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Gilead Sciences (United States) · USMayo Clinic in Arizona · USCancer Prevention Institute of California · USDana-Farber Cancer Institute · USJewish General Hospital · CAPrincess Margaret Cancer Centre · CAUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overBenzamidesFemaleHumansJanus Kinase 1Janus Kinase 2MaleMiddle AgedPrimary MyelofibrosisProtein Kinase InhibitorsPyrimidinesThrombocytosisBenzamidesJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideProtein Kinase InhibitorsPyrimidines

Identifiers

PMID29263442
OpenAlexW2768722269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.